Integra LifeSciences Holdings Corp 
IART manufactures and sells surgical instruments, neurosurgical products, and wound care solutions for neurosurgery, neurocritical care, otolaryngology, orthopedics, and general surgery. The stock has fallen over the past few years due to earnings misses / lowered earnings per share guidance, slow revenue growth, and operational challenges / recalls. But the company has been around since 1989 (endured many ups and downs during that time), has over 4,000 employees, a book value near $20 (undervalued), a forward price-to-earnings between 6x-9x (depending on the source), and revenue growth beyond 2025 and into 2028. Debt is slightly high with a debt-to-equity ratio of 1.2x and a quick ratio near 0.8x (company may have difficulty meeting its short-term obligations with its most liquid assets), it is thus a risky play. But the valuation and potential turnaround should get some attention.
From a technical analysis perspective, the stock price has entered and exited my "crash" simple moving average area 3 times now (see green lines). While I think $10 is likely in the near-term, it appears the stock *may* be forming a bottom - especially given the book value is more than 60% from the current price. But, as always, medical device stocks are always a major investment risk, so due diligence is needed.
Thus, at $12.39,IART is in a buy zone with a note regarding the potential for a dip near $10 before a move up. Targets will be kept low for a swing trade.
Targets:
IART manufactures and sells surgical instruments, neurosurgical products, and wound care solutions for neurosurgery, neurocritical care, otolaryngology, orthopedics, and general surgery. The stock has fallen over the past few years due to earnings misses / lowered earnings per share guidance, slow revenue growth, and operational challenges / recalls. But the company has been around since 1989 (endured many ups and downs during that time), has over 4,000 employees, a book value near $20 (undervalued), a forward price-to-earnings between 6x-9x (depending on the source), and revenue growth beyond 2025 and into 2028. Debt is slightly high with a debt-to-equity ratio of 1.2x and a quick ratio near 0.8x (company may have difficulty meeting its short-term obligations with its most liquid assets), it is thus a risky play. But the valuation and potential turnaround should get some attention.From a technical analysis perspective, the stock price has entered and exited my "crash" simple moving average area 3 times now (see green lines). While I think $10 is likely in the near-term, it appears the stock *may* be forming a bottom - especially given the book value is more than 60% from the current price. But, as always, medical device stocks are always a major investment risk, so due diligence is needed.
Thus, at $12.39,
IART is in a buy zone with a note regarding the potential for a dip near $10 before a move up. Targets will be kept low for a swing trade.Targets:
- $15.00 (+21.0%)
- $16.50 (+33.2%)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.